Related Experiment Videos
Nonsteroidal progesterone receptor ligands with unprecedented receptor selectivity
S Palmer1, C A Campen, G F Allan
1R.W. Johnson Pharmaceutical Research Institute, 1000 Route 202, PO Box 300, Raritan, NJ 08869, USA.
The Journal of Steroid Biochemistry and Molecular Biology
|February 17, 2001
Summary
New nonsteroidal progesterone receptor ligands, tetrahydropyridazines, show high specificity and potential for clinical use. These compounds mimic progestin effects in cells and animal models, with some exhibiting antagonist activity.
Area of Science:
- Endocrinology
- Pharmacology
- Molecular Biology
Background:
- The progesterone receptor (PR) is a key target for hormone-dependent diseases.
- Development of selective nonsteroidal PR ligands is crucial for therapeutic applications.
Purpose of the Study:
- To characterize a novel series of nonsteroidal progesterone receptor ligands, the tetrahydropyridazines.
- To evaluate their affinity, specificity, and functional activity in vitro and in vivo.
Main Methods:
- Synthesis and characterization of tetrahydropyridazine compounds.
- In vitro assays measuring receptor binding affinity and gene expression.
- In vivo studies in rabbits and monkeys assessing hormonal effects and ovulation inhibition.
Main Results:
- Tetrahydropyridazines, like RWJ 26819, exhibit high affinity and specificity for the PR over other steroid receptors.
- RWJ 26819 stimulates PR binding to DNA, gene expression, and cell proliferation in breast cancer cells.
- In vivo, RWJ 26819 induces uterine changes in rabbits and inhibits ovulation in monkeys.
Conclusions:
- Tetrahydropyridazines represent a promising class of selective nonsteroidal PR modulators.
- Their enhanced selectivity suggests potential for effective clinical applications despite lower potency in some models.
- Both agonist and antagonist activities were observed within this compound series.